Phosphorodiamidate morpholino oligonucleotides (PMOs)
constitute
3 out of the 11 FDA-approved oligonucleotide-based drugs in the last
6 years. PMOs can effectively silence disease-causing genes and modify
splicing. However, PMO synthesis has remained challenging for a variety
of reasons: inefficient deprotection and coupling methods and instability
of monomers. Here, we report the development of a suitable combination
of resin supports, deblocking and coupling reagents for synthesizing
PMOs using either trityl or Fmoc-protected chlorophosphoramidate monomers.
The synthesized PMOs using both the methods on a solid support have
been validated for gene silencing in a zebrafish model. The protocol
was successfully transferred into an automated DNA synthesizer to
make several sequences of PMOs, demonstrating for the first time the
adaptation of regular PMOs in a commercial DNA synthesizer. Moreover,
PMOs with longer than 20-mer sequences, including FDA-approved Eteplirsen
(30-mer), were achieved in >20% overall yield that is superior
to
previous reports. Hybridization study shows that PMOs exhibit a higher
binding affinity toward complementary DNA relative to the DNA/DNA
duplex (>6 °C). Additionally, the introduction of Fmoc chemistry
into PMOs opens up the possibility for PMO synthesis in commercial
peptide synthesizers for future development.